Description
Course number 11079
CPD point:20
Cryopen is the obvious choice regarding cryotheraupetic reatment of skin disorders in General Medicine, Pediatrics, OBGYN/Urology, Podiatry, Veterinary and Aesthetic applications.
Through the use of the patented liquid freezing system with N2O gas, our Cryotherapy Device can produce a temperature of -89 °C. In combination with the inbuilt filter, which keeps the clinically sterile N2O gas free of pollution, the low temperature allows for quick, cheap and effective cryotherapy.
Cryopen is a state of the art treatment using extreme cold to safely and painlessly destroy unwanted moles, warts, skin tags and resistant hyper pigmentation. Using no scalpels or chemicals, Cryopen safely, effectively and comfortably removes warts, moles, skin tags and other skin lesions. Removal is virtually pain-free with little or no scarring. Procedures typically last from 30 seconds, so clients can not stay long clinic. Estimate whole procedure takes 5 minutes.
Uses Nitrogen oxide (N2O)
Constant freezing temperature of -89 °C
Valve-lever for accurate dosing
Safety-filter in the cartridge holder
The gold standard in cryotherapy pens
Using nitrous oxide cartridges avoids all of the storage and transportation problems associated with liquid nitrogen
The Cryotherapy Device is a solution for various skin conditions that clients might seek treatment for. These include:
Skin Tags
Warts
Verrucas
Age Spots
Sun Spots
Liver Spots
Cherry Angiomas
Course Requirements: The Course require a minimum of a Level 3 in Beauty Therapy or something equivalent, so please check with the team as we can work on a solution through training so that you to meet the requirements and any missing requirements can be added to the training as and when required.
If you do not have this then you will need to do our A&P training course
Our training is accredited and insurable, requirements may vary from insurer to insurer so we ask all students to check with their own insurer before booking any courses.
Reviews
There are no reviews yet.